Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1382475-35-5Abiraterone Mesylate

● Under Development

Catalogue No.:	VL830040
CAS No.:	1382475-35-5
Mol. Formula:	C25H33NO3S
Mol. Weight:	427.6 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 1382475-35-5

Parent drug

Abiraterone

IUPAC Name

(3S, 10R, 13S)-10, 13-dimethyl-17-(pyridin-3-yl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl methanesulfonate

Pharmacopoeial Synonyms

N/A

Other Synonyms

Abiraterone Acetate P-Toluene Sulfonyl Ester

Smiles

CS(=O)(O[C@H]1CC[C@]2(C)C3CC[C@]4(C)C(C5=CC=CN=C5)=CCC4C3CC=C2C1)=O

InChI

InChI=1S/C25H33NO3S/c1-24-12-10-19(29-30(3,27)28)15-18(24)6-7-20-22-9-8-21(17-5-4-14-26-16-17)25(22,2)13-11-23(20)24/h4-6,8,14,16,19-20,22-23H,7,9-13,15H2,1-3H3/t19-,20?,22?,23?,24-,25+/m0/s1

Description

Abiraterone Mesylate is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Abiraterone. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Abiraterone Mesylate or (3S,10R,13S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl methanesulfonate, it is a active inhibitor of the steroidal enzyme CYP17A1 and is used in the treatment of prostate cancer.

References

Thakur, Abhimanyu, et al. â€œAbiraterone Acetate in the Treatment of Prostate Cancer.â€ Biomedicine & Pharmacotherapy, vol. 101, May 2018, pp. 211â€“218, 10.1016/j.biopha.2018.02.067.